Chris Markoch

Chris Markoch

InvestorPlace Contributor

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

It’s Time For Growth Investors to Jump on Stem

By Chris Markoch, InvestorPlace Contributor

STEM stock has been up and down lately. But with growth investors looking for new opportunities, now is the time to jump on board.

Is Zomedica Making a Change For the Better?

By Chris Markoch, InvestorPlace Contributor

ZOM stock trades below $1 as investors wait to see if recent changes to the company's business model along with potential acquisitions can be a catalyst for revenue.

SOS Stock Simply Faces Too Many Obstacles

By Chris Markoch, InvestorPlace Contributor

SOS stock was falling before the recent selloff in cryptocurrencies. Recent financial results are encouraging, but the stock still looks overvalued.

Litecoin Is Worth a Look For Its Long-Term Viability

By Chris Markoch, InvestorPlace Contributor

Nobody can say predict the short-term outlook for cryptocurrencies. But if you look past the volatility, Litecoin is a sound option.

Clover Health Is Only For the Most Risk-Tolerant Investors

By Chris Markoch, InvestorPlace Contributor

Despite strong revenue numbers, CLOV stock is facing heavy short interest. But risk-tolerant investors may see it as a buying opportunity.

Load More